Your browser doesn't support javascript.
loading
Population pharmacokinetics of roxadustat in Japanese dialysis-dependent chronic kidney disease patients with anaemia.
Takada, Akitsugu; Shibata, Tomohisa; Shiga, Takanori; Groenendaal-van de Meent, Dorien; Komatsu, Kanji.
Afiliação
  • Takada A; Astellas Pharma Global Development, Inc., Illinois, USA.
  • Shibata T; Astellas Pharma, Inc., Tokyo, Japan.
  • Shiga T; Astellas Pharma, Inc., Tokyo, Japan.
  • Groenendaal-van de Meent D; Astellas Pharma Europe B.V, Leiden, Netherlands.
  • Komatsu K; Astellas Pharma, Inc., Tokyo, Japan.
Br J Clin Pharmacol ; 88(2): 787-797, 2022 02.
Article em En | MEDLINE | ID: mdl-34350625
ABSTRACT

AIMS:

Our objective was to develop a population pharmacokinetic (PK) model to describe roxadustat plasma concentrations in Japanese dialysis-dependent chronic kidney disease (DD-CKD) patients with renal anaemia and to identify the covariate factors that affect exposure of roxadustat.

METHODS:

In total, 367 patients (male, 256; female, 111) contributing 1285 concentration values from 4 clinical studies were analysed using a nonlinear mixed-effects modelling approach. Candidate covariates included clinical characteristics hypothesized to affect roxadustat clearance and bioavailability, such as demographics, hepatic parameters and concomitant drugs.

RESULTS:

The roxadustat PK data in Japanese DD-CKD patients with renal anaemia were well described by a 2-compartment disposition model with first-order absorption and interindividual variability on clearance, central volume of distribution and absorption rate constant. Age was identified as a significant covariate on clearance. PK profiles of haemodialysis and peritoneal dialysis patients were comparable. Eighty-two percent of patients were administered at least 1 phosphate binder (PB). The effect of PBs on roxadustat concentration was modelled as a decrease in bioavailability. Staggered administration of PBs reduced the effect on roxadustat bioavailability. The clinical impact of all covariates on roxadustat PK was mild and manageable as the roxadustat dose was titrated based on haemoglobin level and administered starting from a low dose.

CONCLUSION:

Roxadustat PK in Japanese DD-CKD patients were successfully described by a population PK model. The identified key covariates included coadministration of PBs on the roxadustat bioavailability and age on clearance of roxadustat.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Insuficiência Renal Crônica / Anemia Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Female / Humans / Male País/Região como assunto: Asia Idioma: En Revista: Br J Clin Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Insuficiência Renal Crônica / Anemia Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Female / Humans / Male País/Região como assunto: Asia Idioma: En Revista: Br J Clin Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos